March 5 (Reuters) – Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Shares of Tenaya were up more than 11% in premarket trading.
Here are some details:
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath)
